MedTrace Logo

Outcome and Risk Factors For Mortality in Peritoneal Dialysis Patients: 20 Years Experience in a Single Turkish Center

NCT02922270 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 277

Last updated 2016-10-24

No results posted yet for this study

Summary

INTRODUCTION AND AIMS: The aims of this study were to evaluate patient and technique survival rates, investigate peritonitis rates and evaluate factors affecting mortality in peritoneal dialysis (PD) patients over a period of 20 years at Istanbul Faculty of Medicine Peritoneal Dialysis Unit.

METHODS: Two hundred seventy seven patients have received PD as renal replacement therapy (RRT) over a period of 20 years. After exclusion of patients with follow-up shorter than 3 months and patients whose data were not available, 250 patients were examined retrospectively. Data for sex, age, primary disease, comorbidities, follow up duration, cause of death, and cause of technique failure were collected from medical records.

Conditions

  • Therapeutic Procedural Complication

Interventions

OTHER

Peritoneal dialysis patients at the Istanbul Medical Faculty

The aims of this study were to evaluate patient and technique survival rates, investigate peritonitis rates and evaluate factors affecting mortality in peritoneal dialysis (PD) patients over a period of 20 years at Istanbul Faculty of Medicine Peritoneal Dialysis Unit.

Sponsors & Collaborators

  • Istanbul University

    lead OTHER

Principal Investigators

  • Yasar Caliskan, Dr. · Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1995-10-31
Primary Completion
2015-10-31
Completion
2015-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02922270 on ClinicalTrials.gov